Evidence map›Paper›PMID 40886107›Full record

ArticleCancer2025

Optimizing treatment for platinum-resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab.

Yasunori Yoshino, Akiko Furusawa, Katsuhiko Nara, Ayumi Taguchi, Masako Ikemura, Hideo Arai, Tsubasa Hiraki, Aya Ishizaka, Saki Tsuchimochi, Harunori Honjoh and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yasunori YoshinoDepartment of Gynecology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Akiko FurusawaDepartment of Gynecology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Katsuhiko NaraDepartment of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.
Ayumi TaguchiDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5491-3871
Masako IkemuraDepartment of Pathology, The University of Tokyo, Tokyo, Japan.
Hideo AraiDepartment of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Tsubasa HirakiDepartment of Pathology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Aya IshizakaDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
Saki TsuchimochiDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
Harunori HonjohDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
Naoyuki MiyasakaDepartment of Obstetrics and Gynecology, Institute of Science Tokyo, Tokyo, Japan.
Yasuyuki HirashimaDepartment of Gynecology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Kenbun SoneDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
Nao KinoDepartment of Gynecology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.

Funding

Bridging the Gap Between R&d and the IDeal society J0125252401h0001Japan Society for the Promotion of Science 24H02660
6 · The paper itself

Abstract

backgroundPlatinum-resistant (PR) ovarian clear cell carcinoma (OCCC) is highly resistant to chemotherapy and has a poor prognosis. Both in-vitro and clinical studies have suggested that gemcitabine (GEM) is particularly effective against OCCC. Moreover, a combination with bevacizumab (Bev) is expected to enhance the efficacy of chemotherapy.

methodsTo clarify these effects, the authors conducted a multicenter, retrospective cohort study of 130 patients who received treatment single-agent chemotherapy, with or without Bev, for PR-OCCC. The effects of loss of AT-rich interaction domain 1A (ARID1A) protein expression also were assessed.

resultsPatients who received GEM as their first regimen achieved better overall survival (OS) than those who received other agents (median OS, 15.2 vs. 11.0 months; hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.41-0.96; p = .032). Bev combination therapies demonstrated a significantly improved time to treatment failure compared with chemotherapy alone (6.6 vs. 2.7 months; HR, 0.61; 95% CI, 0.41-0.87; p = .009) and showed a trend toward longer OS (23.3 vs. 9.8 months; HR, 0.62; 95% CI, 0.34-1.05; p = .085). ARID1A status did not affect OS in the overall group or in the group that received GEM as the first-line regimen (p = .41 and p = .31, respectively).

conclusionsCollectively, the current findings suggest that GEM, particularly as a first-line treatment, may improve the prognosis of patients with PR-OCCC. Moreover, Bev combination therapy is a promising option for treating PR-OCCC.

Indexed as

Adenocarcinoma, Clear CellAntineoplastic Combined Chemotherapy ProtocolsBevacizumabDeoxycytidineDrug Resistance, NeoplasmOvarian NeoplasmsAdultAgedDNA-Binding ProteinsFemaleGemcitabineHumansMiddle AgedPrognosisRetrospective StudiesTranscription FactorsARID1A protein, humanBevacizumabDeoxycytidineDNA-Binding ProteinsGemcitabineTranscription FactorsAT‐rich interaction domain 1A (ARID1A)bevacizumabgemcitabineovarian clear cell carcinomaplatinum resistance

Identifiers

PMID40886107
PMCPMC12398905

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.